See the DrugPatentWatch profile for Ubrelvy
When will Ubrelvy become available as a generic?
Ubrelvy (ubrogepant) is currently under patent protection, and its generic version is not yet available. The earliest a generic version could potentially be introduced is after the expiration of its primary patents.
What are Ubrelvy's patent expiry dates?
Ubrelvy has several patents protecting it. For instance, U.S. Patent No. 9,380,945, which covers methods of treating migraine, is set to expire on November 28, 2031. Other patents related to the compound and its uses have different expiration dates, with some extending into 2036. Specific details on all Ubrelvy patents can be found on DrugPatentWatch.com [1].
How does Ubrelvy's patent situation affect generic competition?
The existing patents on Ubrelvy would generally prevent generic manufacturers from launching their versions until these patents expire. However, patent challenges or settlements could lead to earlier generic entry. As of now, no generic Ubrelvy has been approved by the FDA [2].
Can biosimilars of Ubrelvy be introduced?
Ubrelvy is a small molecule drug, not a biologic. Therefore, biosimilars, which are for biologic drugs, are not applicable. The generic equivalent for small molecule drugs like Ubrelvy is simply called a generic drug [3].
What are the potential market impacts of Ubrelvy generics?
The introduction of generic Ubrelvy would likely lead to a significant decrease in its price, making the treatment more accessible to patients. This would also increase competition in the oral CGRP antagonist market for migraine treatment [2].
Who manufactures Ubrelvy?
Ubrelvy is manufactured by AbbVie Inc. [4].
What is Ubrelvy used for?
Ubrelvy is a prescription medication used for the acute treatment of migraine with or without aura in adults [5].
How does Ubrelvy work?
Ubrelvy is a calcitonin gene-related peptide (CGRP) receptor antagonist. It works by blocking the action of CGRP, a molecule that plays a role in migraine pain and inflammation [5].
What are the side effects of Ubrelvy?
The most common side effects of Ubrelvy include nausea, fatigue, and dry mouth [5].
What are alternative treatments for migraine?
Other acute migraine treatments include triptans, ergots, and other CGRP antagonists. Non-pharmacological approaches and preventative medications are also options for managing migraines [5].
---
Sources:
1. https://drugpatentwatch.com/drugs/ubrelvy
2. Information based on general understanding of US drug patent laws and market dynamics for branded drugs.
3. U.S. Food & Drug Administration. (n.d.). Biosimilar Product Information. Retrieved from https://www.fda.gov/drugs/biosimilars/biosimilar-product-information
4. AbbVie Inc. (n.d.). AbbVie Completes Acquisition of Allergan. Retrieved from https://news.abbvie.com/news/abbvie-completes-acquisition-of-allergan/default.aspx (Note: Ubrelvy was originally developed by Allergan, which was acquired by AbbVie.)
5. Ubrelvy prescribing information.